↓ Skip to main content

Etoposide damages female germ cells in the developing ovary

Overview of attention for article published in BMC Cancer, August 2016
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • One of the highest-scoring outputs from this source (#2 of 5,907)
  • High Attention Score compared to outputs of the same age (99th percentile)

Mentioned by

110 news outlets
1 blog
14 tweeters
2 Facebook pages


20 Dimensions

Readers on

27 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Etoposide damages female germ cells in the developing ovary
Published in
BMC Cancer, August 2016
DOI 10.1186/s12885-016-2505-9
Pubmed ID

Agnes Stefansdottir, Zoe C. Johnston, Nicola Powles-Glover, Richard A. Anderson, Ian R. Adams, Norah Spears


As with many anti-cancer drugs, the topoisomerase II inhibitor etoposide is considered safe for administration to women in the second and third trimesters of pregnancy, but assessment of effects on the developing fetus have been limited. The purpose of this research was to examine the effect of etoposide on germ cells in the developing ovary. Mouse ovary tissue culture was used as the experimental model, thus allowing us to examine effects of etoposide on all stages of germ cell development in the same way, in vitro. Fetal ovaries from embryonic day 13.5 CD1 mice or neonatal ovaries from postnatal day 0 CD1 mice were cultured with 50-150 ng ml(-1) or 50-200 ng ml(-1) etoposide respectively, concentrations that are low relative to that in patient serum. When fetal ovaries were treated prior to follicle formation, etoposide resulted in dose-dependent damage, with 150 ng ml(-1) inducing a near-complete absence of healthy follicles. In contrast, treatment of neonatal ovaries, after follicle formation, had no effect on follicle numbers and only a minor effect on follicle health, even at 200 ng ml(-1). The sensitivity of female germ cells to etoposide coincided with topoisomerase IIα expression: in the developing ovary of both mouse and human, topoisomerase IIα was expressed in germ cells only prior to follicle formation. Exposure of pre-follicular ovaries, in which topoisomerase IIα expression was germ cell-specific, resulted in a near-complete elimination of germ cells prior to follicle formation, with the remaining germ cells going on to form unhealthy follicles by the end of culture. In contrast, exposure to follicle-enclosed oocytes, which no longer expressed topoisomerase IIα in the germ cells, had no effect on total follicle numbers or health, the only effect seen specific to transitional follicles. Results indicate the potential for adverse effects on fetal ovarian development if etoposide is administered to pregnant women when germ cells are not yet enclosed within ovarian follicles, a process that starts at approximately 17 weeks gestation and is only complete towards the end of pregnancy.

Twitter Demographics

The data shown below were collected from the profiles of 14 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 27 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Spain 1 4%
Italy 1 4%
Unknown 25 93%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 5 19%
Student > Master 5 19%
Researcher 3 11%
Student > Bachelor 3 11%
Student > Postgraduate 2 7%
Other 3 11%
Unknown 6 22%
Readers by discipline Count As %
Biochemistry, Genetics and Molecular Biology 7 26%
Agricultural and Biological Sciences 6 22%
Medicine and Dentistry 5 19%
Pharmacology, Toxicology and Pharmaceutical Science 1 4%
Social Sciences 1 4%
Other 1 4%
Unknown 6 22%

Attention Score in Context

This research output has an Altmetric Attention Score of 879. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 30 August 2017.
All research outputs
of 15,922,017 outputs
Outputs from BMC Cancer
of 5,907 outputs
Outputs of similar age
of 268,095 outputs
Outputs of similar age from BMC Cancer
of 2 outputs
Altmetric has tracked 15,922,017 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 99th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 5,907 research outputs from this source. They receive a mean Attention Score of 4.1. This one has done particularly well, scoring higher than 99% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 268,095 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 99% of its contemporaries.
We're also able to compare this research output to 2 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them